AB Science S.A. is a pharmaceutical firm focused on discovering, advancing, and commercializing protein kinase inhibitors for both human and animal therapeutic applications. The company's primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for various conditions including prostate and pancreatic cancers, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, it is in Phase II trials for managing Covid-19. Beyond masitinib, AB Science is also advancing AB8939, a synthetic microtubule destabilizer designed to treat acute myeloid leukemia. Another product in development is AB20001, a combination therapy involving masitinib and isoquercetin, which is currently in Phase II trials to assess its safety and effectiveness in hospitalized patients experiencing moderate to severe COVID-19. In the European market, masitinib is sold under the brand name Masivet. Established in 2001, AB Science S.A. operates from its headquarters in Paris, France.
